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Background: The glutamate model of schizophrenia proposes that altered 
glutamatergic neurotransmission is fundamental to the development of the disorder. In 
addition, its potential to mediate neurotoxicity raises the possibility that glutamate 
dysfunction could underlie neuroanatomical changes in schizophrenia. Here we 
determine whether changes in brain glutamate are present in subjects at ultra high risk 
of developing psychosis, and whether these changes are related to reductions in 
cortical gray matter volume.  
Methods: Twenty-seven individuals with an At Risk Mental State (ARMS) and a 
group of 27 healthy volunteers underwent proton magnetic resonance spectroscopy 
and volumetric proton magnetic resonance imaging using a 3 Tesla scanner. 
Glutamate and glutamine levels were measured in anterior cingulate, left 
hippocampus and left thalamus. These measures were then related to cortical gray 
matter volume.  
Results: ARMS subjects had significantly lower levels of glutamate than controls in 
the thalamus (p<0.05), but higher glutamine in the anterior cingulate (p<0.05). Within 
the ARMS group, the level of thalamic glutamate was directly correlated with gray 
matter volume in the medial temporal cortex and insula (p<0.01).  
Conclusions: This study provides the first evidence that brain glutamate function is 
perturbed in people with prodromal signs of schizophrenia, and that glutamatergic 
dysfunction is associated with a reduction in gray matter volume in brain regions 
thought to be critical to the pathogenesis of the disorder. These findings support the 
hypothesis that drugs affecting the glutamate system may be of benefit in the early 
stages of psychotic illness.
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Introduction 
Altered brain glutamatergic transmission is thought to be one of the primary 
neurochemical abnormalities in schizophrenia (1-3). Uncompetitive NMDA receptor 
antagonists such as phencyclidine (PCP) and ketamine consistently induce effects 
resembling the positive and negative symptoms of schizophrenia in humans. These 
drugs have been shown to cause an increase in glutamate release in prefrontal cortex 
in animal studies (4,5), and to be associated with toxic changes in cortical neurons 
(6,7). These effects are hypothesised to occur through preferential blockade of 
NMDA receptors expressed on GABAergic interneurons, leading to a disinhibition of 
glutamatergic neurons projecting to the cerebral cortex (6). The thalamus may be the 
primary site where this block occurs: direct injection of NMDA receptor antagonists 
into cortical brain regions does not cause glutamate (Glu) release (4), or neuronal 
toxicity (7), whereas injection into thalamus induces an identical pattern of toxic 
change in the cortex to that seen with systemic administration (7). Moreover, injection 
of GABA agonists into thalamus prevents the cortical changes induced by systemic 
administration of NMDA receptor anagonists (7). 
 
Neuroimaging studies in patients with schizophrenia have provided some evidence of 
NMDA receptor dysfunction, and of a disinhibition of Glu release. One single photon 
emission computed tomography (SPECT) study of medication-free patients found that 
they had reduced hippocampal NMDA receptor binding relative to whole cortex, and 
that this was partially reversed in patients on antipsychotic medication (8). Another 
study, using proton magnetic resonance spectroscopy (1H-MRS) found that 
unmedicated first episode patients had elevated glutamine (Gln) in anterior cingulate 
(9). Patients with first episode and chronic schizophrenia have also been found to 
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have elevated Gln levels in the thalamus (9,10). Although 1H-MRS cannot distinguish 
between metabolic and neurotransmitter Glu, there is evidence that 80-100% of Glu in 
the brain is rapidly cycled to Gln through its release as a neurotransmitter (11).  As 
Gln is generated from Glu in astrocytes after the release of Glu from the synapse, the 
level of Gln measured with 1H-MRS has been suggested as a marker of the degree of 
Glu release in a given region (9). In keeping with this hypothesis, ketamine led to 
increased anterior cingulate levels of Gln in healthy controls, measured using 1H-
MRS (12). 
 
Structural MRI studies of schizophrenia show robust reductions in regional gray 
matter volume (13). Longitudinal reductions in gray matter volume appear to occur 
after the first episode of schizophrenia, and the degree of gray matter loss in the early 
phase of the illness may predict subsequent clinical outcome (14,15). The underlying 
basis of these volumetric changes is unknown. The role of elevated synaptic Glu 
release is of particular interest in this context, as its potential for excitotoxicity and 
modulation of plasticity through effects on NMDA receptors could give rise to 
changes in gray matter volume (16,17). 
 
The first episode of schizophrenia is usually preceded by a prodromal phase 
characterized by attenuated psychotic symptoms in the context of a marked decline in 
global function. This At Risk Mental State (ARMS) is associated with a greatly 
increased risk of developing psychosis, with a transition rate of around 35% within 24 
months (18,19). Volumetric MRI studies of the ARMS indicate that it is associated 
with reductions in regional gray matter volume that are qualitatively similar but less 
severe than are evident in schizophrenia (20-22).  
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In this study we used 1H-MRS and volumetric MRI to address the question of 
whether glutamatergic abnormalities are present in ARMS subjects and, if so, how 
they are related to the alterations in gray matter volume that are evident in this group. 
We tested the following hypotheses: 1) Regional Glu and Gln levels would be 
significantly different in ARMS subjects and controls 2) ARMS subjects would have 
reduced regional gray matter volume relative to controls 3) The alteration in Glu and 
Gln levels in the ARMS group would be correlated with relative reductions in gray 
matter volume. 
 
Methods 
Ethics and power calculation 
Ethical approval for this study was obtained from the South London and Maudsley 
NHS Trust Ethics Committee. Sample sizes were estimated from a pilot study of 4 
healthy controls with test-retest (mean Glu + Gln=17.02 institutional units, (iu), 
SD=3.63). We used G*Power statistical software (23), to calculate that 26 subjects in 
each group would be required to detect a 20% difference in anterior cingulate Glu + 
Gln with a power of 0.9 (alpha=0.05, two tailed).  
Informed consent 
ARMS subjects were recruited from OASIS (Outreach and Support in South London), 
part of the South London and Maudsley NHS Trust. The study was explained to them 
and they were given a written description of the study. Controls were recruited from 
the same geographical area through advertisements that outlined the study. All 
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subjects who expressed interest in participation were offered a face-to-face interview, 
where the full details of the study, including its possible risks and benefits were 
explained. They were then invited to give written consent to take part, and told that 
they were free to withdraw from the study at any time without giving a reason. 
 
Sample 
We compared twenty-seven individuals meeting PACE criteria for the ARMS (24), 
and twenty-seven healthy volunteers. Controls had no personal history of psychiatric 
symptoms, psychotropic medication or medical illness, and no family history of 
psychiatric illness.  For both groups, exclusion criteria included history of severe head 
injury (loss of consciousness for over 5 minutes), drug or alcohol dependence, 
metallic implants, and pregnancy. 
 
Pre-scan interview 
Prior to scanning, all subjects were interviewed about their family and personal 
psychiatric history, current and past medication use and current and past use of 
alcohol, tobacco and illicit drugs. Symptomatology in both groups was assessed using 
the Comprehensive Assessment of At-Risk Mental State (CAARMS) (24), The 
Positive and Negative Symptom Scale (PANSS) (25), and the Hamilton Depression 
and Anxiety Scales (HAM-D and HAM-A) (26,27). 
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Selection of regions of interest 
We selected the anterior cingulate cortex and the left thalamus as regions of interest 
(ROIs) for spectroscopic analysis, on the basis of previous findings of altered Gln 
levels in anterior cingulate cortex in patients with schizophrenia (9), and of altered 
Gln levels in the left thalamus in schizophrenia (9,10,28). The thalamus is of 
additional interest, as NMDA receptor dysfunction at this site putatively underlies the 
elevation of cortical glutamatergic transmission that is thought to occur in 
schizophrenia (6,7). The third ROI chosen was the left hippocampus, the 
hippocampus having been implicated as a site of glutamatergic abnormality (8,29,30), 
as well as a commonly reported site of volume loss in schizophrenia (31).  
 
Volumetric MRI protocol 
All subjects underwent volumetric MRI and 1H-MRS scanning. Scanning took place 
on a General Electric (Milwaukee, USA) 3 Tesla HDx Magnetic Resonance system. 
After positioning the subject in the scanner with a foam rest under their knees, an 
initial localizer scan was performed to measure the interhemispheric angle and the 
AC-PC line (the line passing through the upper part of the anterior commisure and the 
lower part of the posterior commisure – approximated from the anterior and posterior 
corpus callosum).  
 
Structural images were acquired using an axial 2D T2 weighted Fast Spin Echo scan 
and an axial fast FLAIR scan (total scan time 5 minutes), both prescribed parallel to 
the AC-PC line. These were followed by a whole brain 3D coronal IR-SPGR 
(inversion recovery prepared spoiled gradient echo) scan, prescribed from the midline 
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sagittal localizer, giving isotropic 1.1mm resolution in a scan time of approximately 6 
minutes (TE = 2.82ms; TR = 6.96ms; TI = 450ms; flip angle = 20º). The IR-SPGR 
scans were used for localization of the spectroscopy ROIs, and were subsequently 
segmented into gray matter, white matter and CSF using SPM2 to allow correction of 
the spectroscopy results for partial volume CSF contamination. IR-SPGR scans were 
also segmented with SPM5 for voxel based morphometry, with non-parametric 
statistical testing of group differences in gray matter volume being performed using 
BAMM (Brain Activation and Morphological Mapping; http://www-
bmu.psychiatry.cam.ac.uk/BAMM/index.html). 
 
1H-MRS protocol 
All subjects were scanned using the scanner’s body coil for transmit, and the 
manufacturer’s standard 8-channel coil for receive. 1H-MRS spectra (PRESS - Point 
RESolved Spectroscopy - TE=30ms, TR=3000ms, 96 averages) were acquired in the 
anterior cingulate, left hippocampus and left thalamus. We employed the standard GE 
PROBE (proton brain exam) sequence, which uses a standardized chemically 
selective suppression (CHESS) water suppression routine. For each metabolite 
spectrum, unsuppressed water reference spectra (16 averages) were also acquired as 
part of the standard acquisition. Shimming and water suppression were optimized, 
with auto-prescan being performed twice prior to each scan. The anterior cingulate 
ROI was prescribed from the midline sagittal localiser, and the centre of the 20mm x 
20mm x 20mm ROI was placed 13mm above the anterior section of the Genu of 
Corpus Callosum at 90
o
 to the AC-PC line. A 20mm x 20mm x 15mm (right-left, 
anterior-posterior, superior-inferior) left hippocampal ROI was prescribed from a 
coronal SPGR image. A 15mm x 20mm x 20mm (right-left, anterior-posterior, 
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superior-inferior) left thalamus ROI was defined at the point in the coronal slices 
where the thalamus was widest, using sagittal and coronal localisers to ensure that the 
ROI was clear of CSF contamination. After the subject left the scanner, each scanning 
session concluded with the collection of a PRESS spectrum from a phantom 
containing standard concentrations of brain metabolites to allow monitoring of 
scanner drift or step-changes with scanner software updates over the period of data 
acquisition for this study. 
 
1H-MRS quantification

 
All spectra were analysed using LCModel version 6.1-4F (32). The raw spectral data 
were read into LCMgui, the graphical user interface for LCModel, which 
automatically combined the data from the 8-channel coil with a weighted coherent 
average over the 8 receive channels using the intensity of the first point of the FID of 
the unsuppressed water reference from each coil. A standard basis set of 16 
metabolites (L-alanine, aspartate, creatine, phosphocreatine, GABA, glucose, 
glutamine, glutamate, glycerophosphocholine, glycine, myo-inositol, L-lactate, N-
acetylaspartate, N-acetylaspartylglutamate, phosphocholine, taurine), included as part 
of LCModel, and acquired with the same field strength (3T), localization sequence 
(PRESS) and echo time (30ms) as our study was used. Model metabolites and 
concentrations employed in the basis set are fully detailed in the LCModel manual 
(http://s-provencher.com/pages/lcm-manual.shtml). 
 
Poorly fitted metabolite peaks (Cramer-Rao minimum variance bounds of more than 
20% reported by LCModel) were excluded from further analysis. Water-scaled Glu, 
Gln and NAA values were corrected for the CSF content of the ROI using the formula 
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Mcorr=M/(1-C) where M is the uncorrected metabolite value and C is the fractional 
CSF content of the ROI. We determined the CSF content of each ROI for each subject 
by extracting the size and location of the ROI from the spectra file headers, and using 
an in-house program to calculate the percentage grey, white and CSF content using 
the segmented IR-SPGR images.  
 
Statistics 
All statistical analyses were performed using SPSS version 16.0 (SPSS inc. Chicago, 
Illinois, USA). A GLM multivariate ANOVA was performed with diagnostic group as 
a factor and levels of Glu and NAA in each region as dependent variables. Due to the 
small number of subjects with well-fitted Gln peaks, group differences in Gln levels 
were entered into the GLM in a subsequent step. The effect of drug use and of 
demographic differences between groups on significantly different metabolite 
measures was studied using linear regression (stepwise). 
 
MRI data analysis 
Segmentation was performed using Statistical Parametric Mapping software (SPM5, 
Wellcome Department of Imaging Neurosciences, University College London, UK). 
Gray matter probability images were then “modulated” (to compensate for the effect 
of spatial normalisation) by multiplying each voxel value by its relative volume 
before and after warping. The segmented images were then smoothed with an 8mm x 
8mm x 8mm Gaussian kernel to reduce noise, and also allow for the effects of small 
residual mis-registrations. Given that structural brain changes are likely to extend 
over a number of contiguous voxels, test statistics incorporating spatial information 
such as 3D cluster mass (the sum of suprathreshold voxel statistics) are generally 
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more powerful than other possible test statistics, which are informed only by data at a 
single voxel (33). As no parametric distribution is known for cluster mass, 
permutation testing was used to assess statistical significance. 
 
Between-group differences in gray matter volume, and correlations of gray matter 
volume difference with significant CSF-corrected metabolite differences were 
analysed by fitting an analysis of covariance (ANCOVA) model at each intracerebral 
voxel in standard space, covarying for total gray matter, using the BAMM package. A 
relatively lenient p-value (p=0.05) was initially set to detect voxels putatively 
demonstrating differences between groups; spatial clusters of such voxels were then 
searched for and the “mass” of each cluster found (the sum of suprathreshold voxel 
statistics it comprises) was tested for significance. Permutation based testing, 
implemented in the BAMM package, was used to assess statistical significance at 
both the voxel and cluster levels (33). At the cluster level, rather than set a single a 
priori p-value below which findings are regarded as significant, the number of clusters 
which would be expected by chance alone for a range of p-values was calculated. The 
statistical threshold for cluster significance for each analysis was then set such that the 
expected number of false positive clusters by chance alone would be less than one 
(33). 
Results 
Subject demographics 
Control and ARMS individuals did not differ in age, sex, ethnicity, social class or IQ 
(measured using NART), but controls had a significantly higher level of education 
than ARMS individuals (Table 1). Eight ARMS individuals but none of the controls 
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had previously taken antidepressant or antipsychotic medication and five of these 
were still taking medication (four had taken quetiapine, but only one was taking it at 
the time of the first scan, one was taking aripiprazole, two were taking citalopram and 
one was taking sertraline). There were no significant group differences in substance or 
alcohol use, but the ARMS subjects were more likely to have used tobacco. 
Clinical measures 
ARMS subjects had significantly higher levels of prodromal, psychotic, anxiety and 
depressive symptoms than controls, as measured using the CAARMS, PANSS, HAM-
A and HAM-D (see table 2). 
1H-MRS measures 
There was no evidence from serial water-scaled phantom measurements of scanner 
drift or step changes in estimated metabolite values during the acqusition period for 
this study. 1H-MRS spectra quality were good in left thalamus and in anterior 
cingulate, with a mean(SD) signal to noise ratio reported by LCModel of 19(4) and 
19(6) respectively, and of reasonable quality in left hippocampus with a mean(SD) 
signal to noise ratio of 12(3). Linewidths reported by LCModel followed a similar 
pattern with mean(SD) of 5.3(1.8) Hz in anterior cingulate, 6.6(1.4) Hz in left 
thalamus and 8.9(3.1) Hz in left hippocampus. There were no significant differences 
in spectral quality between control and ARMS subjects. 
 
Glu (water-scaled, CSF corrected) and NAA in left thalamus were both significantly 
lower in ARMS subjects than controls (F(1,43)=7.545, p=0.008; F(1,43)=7.450, 
p=0.009). There was also a significant elevation of Gln levels in the anterior cingulate 
in ARMS subjects compared to controls (F(1,17)=6.998, p=0.017). Linear regression 
 13 
revealed that these results were best explained by diagnostic status alone: previous 
exposure to psychotropic medication, educational level, and current level of tobacco, 
alcohol or cannabis use did not have any additional predictive value for Glu, Gln, or 
NAA levels. Furthermore, the results remained significant whether or not CSF 
correction was employed, indicating they were not an artefact of the CSF correction.  
 
In keeping with the hypothesis that NAA is a marker for pyramidal cell integrity, Glu 
correlated positively with NAA in all three ROIs. This relationship was stronger in 
anterior cingulate (r=0.703, n=53, p<0.001) and left hippocampus (r=0.550 , n=51, 
p<0.001) than in left thalamus (r=0.331, n=52, p<0.05). 
 
Other measured metabolites, for which we had no a priori hypotheses, have been 
summarized in Table 3. Thalamic creatine was reduced in ARMS subjects, although 
this finding does not survive correction for multiple comparisons. 
 
Group differences in regional gray matter volume 
ARMS subjects had less gray matter volume than controls in the orbitofrontal cortex 
bilaterally, extending into the adjacent ventral anterior cingulate cortex, but relatively 
more gray matter volume in left cerebellum and left occipital cortex (cluster threshold 
p<0.007; see figure 1).  
 
Relationship between 1H-MRS measures and gray matter volume 
In ARMS subjects, levels of Glu in left thalamus were directly correlated with gray 
matter volume in the left prefrontal cortex, insula, cingulate, superior temporal gyrus 
and temporal pole, as well as bilaterally in the cerebellum and lingual gyrus (cluster 
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p<0.005; Figure 2). In these regions, the lower the thalamic Glu level, the smaller the 
volume of gray matter. Conversely, there was an inverse correlation between left 
thalamic Glu and the volume of the dorsal anterior cingulate extending to the 
posterior cingulate gyrus (cluster p<0.005; Figure 2). Thalamic NAA did not correlate 
with gray matter in any brain region in ARMS subjects.  
 
Anterior cingulate Gln in the ARMS subjects was inversely correlated with gray 
matter in left cerebellum, and directly correlated with gray matter volume in the 
posterior cingulate gyrus (threshold p<0.004). This region was contiguous with, but 
did not significantly overlap, the portion of the cingulate gyrus where there was a 
negative correlation with thalamic Glu levels.  
 
We did not have any a priori hypotheses about correlations between Glu or Gln and 
gray matter volume in healthy controls. A post-hoc analysis revealed there were no 
significant correlations between thalamic Glu or NAA and grey matter in healthy 
controls. However, there was an inverse correlation between anterior cingulate Gln 
levels and grey matter volume in medial frontal and orbitofrontal cortex, and a 
positive correlation with grey matter volume in right temporal cortex. 
 
Discussion 
This is the first 1H-MRS study to examine Glu function in subjects experiencing 
prodromal symptoms of schizophrenia, and the first study to examine the relationship 
between Glu levels in these subjects and gray matter volume. The findings are not 
attributable to effects of antipsychotic medication, as most of the ARMS subjects 
 15 
were medication naive, and inclusion of medication as a factor in the analysis had no 
effect on the results. 
 
There are some potential limitations to this work that should be considered. 1H-MRS 
is a difficult imaging method to apply, with a potential for erroneous results if poor 
quality spectra are included in the analysis (34). In the present study this led to us 
having to exclude a large number of Gln estimates, particularly in the left 
hippocampal and thalamic ROIs. The reason for the difficulties in measuring Gln 
probably relate to the fact that this study was performed using a 3T scanner, whereas 
groups studying Gln as a separate peak have generally employed 4T scanners 
(9,10,12). The fact that we could only obtain reliable measures of Gln in anterior 
cingulate is likely to be a result of the better quality (lower linewidth) spectra 
obtained from this region. Poor fitting of Gln could also, theoretically, have led to 
overestimation of the overlying NAA peaks (35).  
 
Differences in tissue relaxation times between patients and controls, as previously 
reported in patients with schizophrenia (36), could lead to differences in estimation of 
water-scaled metabolite concentrations. We investigated this possibility by 
extrapolating the previously reported values to 3T and found that, if differences in 
tissue water relaxation were as marked in ARMS subjects as in patients with 
schizophrenia, metabolite estimation could deviate by a maximum error of 3%.  
 
The two groups we studied were not matched for tobacco use, with higher rates of use 
in the ARMS subjects. This is consistent with evidence that patients with 
schizophrenia use more tobacco than patients with other psychiatric disorders and 
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controls (37), and that adolescents who later develop schizophrenia have higher rates 
of smoking before the onset of illness (38). However, history of tobacco use was not 
found to be a predictive factor for either thalamic Glu or NAA or anterior cingulate 
Gln.  
 
We found reduced regional gray matter volume in ARMS subjects compared to 
healthy controls. This is consistent with the results of previous MRI studies (20-22), 
which indicate that reductions in regional gray matter volume are evident in people 
with prodromal symptoms of psychosis. As in these studies, the location of the 
volumetric findings in the present study correspond to sites of reduced gray matter 
volume in patients with schizophrenia (39). The region of increased gray matter in 
ARMS subjects compared to controls including occipital cortex was in keeping with 
an earlier study with a different cohort of patients, reporting that ARMS subjects who 
underwent transition to psychosis had increased grey matter in occipital cortex 
compared to those who did not (21). 
 
Thalamic Glu and NAA levels in the left thalamus were significantly reduced in the 
ARMS group. 1H-MRS studies in schizophrenia have generally reported elevated 
thalamic Gln levels, and unchanged Glu levels, although these have involved patients 
with established psychosis rather than subjects with prodromal symptoms (9,10,28). 
The reason for the differences between the results of our study and previous studies is 
not clear. The method we used to measure Glu and Gln (LCModel) was different from 
that used by Theberge et al. (9,10,28), who used in-house software (Fitman and LHRI 
Analysis Suite, Theberge - personal communication 25
th
 March 2008). There are 
differences between these two methods of quantifying Glu and Gln: for example, the 
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LCModel uses non-physical model components to perform baseline fitting (spline fit). 
There were also differences between these studies in 1H-MRS acquisition (PRESS vs. 
STEAM), the method for selection of good quality spectra, and in scanner model and 
field strength (3T vs. 4T). Finally, the studies examined quite different groups: we 
examined individuals at high risk of psychosis, whereas the previous studies 
investigated patients with schizophrenia. Interestingly, a previous study found a 
correlation between reductions in NAA in left thalamus in patients with first episode 
psychosis and the length of the preceding prodromal phase (40). 
 
We found that Gln levels in the anterior cingulate cortex were elevated in the ARMS 
group relative to controls. This finding is in keeping with previous reports of 
increased cingulate Gln levels in unmedicated patients with first-episode 
schizophrenia (9), and in the adolescent relatives of patients with schizophrenia (41). 
 
One of the most striking findings was the relationship between thalamic Glu levels in 
the ARMS group and regional gray matter volume. We found that the lower the Glu 
levels, the smaller the gray matter volume in the medial temporal, lateral temporal, 
inferior frontal, insula and cingulate cortex, as well as in the cerebellum. This set of 
areas corresponds closely to the sites of the most robust reductions in volume in MRI 
studies of schizophrenia (39). The finding is also consistent with data from a recent 
1H-MRS and MRI study in schizophrenia, which found that a longitudinal reduction 
in thalamic Gln levels was correlated with a progressive reduction in parietal and 
temporal cortex gray matter volume (28). The correlation between thalamic Glu levels 
and reductions in gray matter volume we observed raises the possibility that changes 
in Glu function might contribute to the structural findings, possibly through 
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disinhibition of thalamocortical pyramidal cells (17). Unexpectedly, the reduction in 
thalamic Glu in the ARMS group was also associated with relatively increased gray 
matter volume in the dorsal and posterior cingulate cortex. It has been suggested that 
increases in gray matter volume might occur in the very early stages of apoptosis (42), 
so it possible that this might be a relatively early effect of disinhibition of 
thalamocortical glutamatergic projections, with a reduction in cortical volume 
occurring at a later stage. We are currently collecting longitudinal 1H-MRS data in 
this sample, which may clarify whether the relationship between thalamic Glu and 
cortical gray matter volume changes over time. 
Conclusions  
This study suggests that cortical and thalamic Glu function are perturbed in people at 
ultra high risk of developing psychosis, and that thalamic reductions in Glu are related 
to alterations in cortical gray matter volume in this group. Future work will determine 
whether thalamic Glu reductions are related to risk of transition to psychosis, and 
whether pharmacological modulation of the Glu system can reduce this risk. 
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Table 1: subject demographics 
 ARMS Control Significance 
Age mean(SD) 25(5) 25(4) P=0.883 
Sex f/m 13/14 14/13 Fisher’s=1.0 
Ethnicity 
Caucasian/African-Caribbean/ se 
Asian/ African/ Asian/ other 
15/2/1/1/2/6 12/7/2/2/3/1 Chi sq=0.426 
Social class (parent’s occupation) 
ab,c1,c2,de, unknown 
2/6/9/3/7 2/14/6/1/4 Chi sq=0.23 
National Adult Reading Test 
mean(SD) 
28.69(12.24) 32.89(7.96) P=0.147 
Current antipsychotic or 
antidepressant medication y/n 
6/21 0/27 Fisher’s=0.023 
Education no qualifications/ 
GCSE/A-level/ degree/higher degree  
2/13/5/7/0 0/3/16/6/2 Chi sq=0.003 
Tobacco (ever used) y/n 19/8 7/20 Fisher’s=0.002 
Alcohol (ever used) y/n 22/5 22/5 Fisher’s=1 
Cannabis (ever used) y/n 19/8 14/13 Fisher’s=0.264 
Cannabis - times taken in previous 
year (SD) 
13.04(44.5) 67.11(223.8) P=0.228 
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Table 2: clinical measures 
 ARMS (n=27) 
Mean(SD) 
Controls (n=27) 
Mean(SD) 
Significance (p) 
CAARMS –abnormalities 
of thought content  
3.3(1.56) 0.15(0.456) <0.001 
CAARMS –perceptual 
abnormalities 
2.37(1.75) 0.37(0.967) <0.001 
CAARMS –speech 
abnormalities 
1.00(1.441) 0.07(0.385) 0.002 
PANSS – Positive 11.67(3.328) 7.26(0.813) <0.001 
PANSS – Negative 8.93(3.05) 7.19(0.786) 0.007 
PANSS – General 22.2(4.46) 16.8(1.18) <0.001 
HAM-A 12.52(11.37) 1.85(2.63) <0.001 
HAM-D 10.52(8.85) 1.63(2.71) <0.001 
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Table 3: metabolite measures (mean(SD)) in anterior cingulate, left thalamus and left 
hippocampus (* p<0.05). 
 Anterior Cingulate Left Hippocampus Left Thalamus 
 Controls ARMS Controls ARMS Controls ARMS 
Glu 11.93(2.01) 
n=27 
12.7(3.14) 
n=26 
7.31(1.65) 
n=27 
6.94(1.54) 
n=24 
7.62(1.32) 
n=26 
6.76(1.18) 
n=26* 
Gln 6.57(1.44) 
n=12 
10.01(3.49) 
n=9* 
5.13(0.82) 
n=4 
5.72(1.03) 
n=5 
5.52(0.69) 
n=2 
4.10(NA) 
n=1 
Glu+Gln 16.63(3.12) 
n=27 
18.28(6.15) 
n=27 
9.91(2.52) 
n=27 
10.27(2.91) 
n=24 
9.75(2.39) 
n=25 
8.37(1.73) 
n=23* 
NAA 10.25(1.14) 
n=27 
11.15(2.27) 
n=27 
7.79(1.08) 
n=27 
7.79(1.57) 
n=26 
11.59(0.89) 
n=27 
10.82(0.89) 
n=27* 
GPC 
(Cho) 
2.56(0.64) 
n=26 
2.6(0.6) 
n=24 
1.91(0.35) 
n=24 
1.91(0.58) 
n=21 
2.02(0.19) 
n=21 
1.91(0.28) 
n=23 
mI 7.65(0.93) 
n=27 
7.91(1.93) 
n=27 
5.88(1.33) 
n=27 
6.11(3.2) 
n=25 
4.14(0.65) 
n=27 
3.99(0.71) 
n=26 
Cre 9.19(1.33) 
n=27 
9.6(2.01) 
n=27 
6.27(1.07) 
n=27 
6.39(1.82) 
n=26 
7.06(0.71) 
n=27 
6.58(0.55) 
n=27* 
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Figure 1: differences in gray matter volume between ARMS and controls (n=27). The 
ARMS group had significantly lower cortical gray matter volumes in orbitofrontal 
cortex bilaterally, extending into the adjacent ventral anterior cingulate cortex, but 
relatively more gray matter volume in left cerebellum and left occipital cortex 
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Figure 2: significant correlations between thalamic glutamate and gray matter volume 
in ARMS subjects (n=26). Thalamic glutamate levels correlated directly with lower 
gray matter volume in left prefrontal cortex, insula, cingulate, superior temporal gyrus 
and temporal pole, as well as bilaterally in the cerebellum and lingual gyrus. They 
showed an inverse correlation with gray matter volume in dorsal anterior cingulate 
extending to the posterior cingulate gyrus. 
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